US20140005124A1 - Cyclosporin derivatives for treating inflammatory diseases and conditions - Google Patents

Cyclosporin derivatives for treating inflammatory diseases and conditions Download PDF

Info

Publication number
US20140005124A1
US20140005124A1 US14/014,728 US201314014728A US2014005124A1 US 20140005124 A1 US20140005124 A1 US 20140005124A1 US 201314014728 A US201314014728 A US 201314014728A US 2014005124 A1 US2014005124 A1 US 2014005124A1
Authority
US
United States
Prior art keywords
radical
cyclosporin
alkyl
group
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/014,728
Inventor
Michael E. Garst
Michael E. Stern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US14/014,728 priority Critical patent/US20140005124A1/en
Publication of US20140005124A1 publication Critical patent/US20140005124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • the invention relates to a method of treating inflammatory, including ocular and/or dermal, diseases and conditions having inflammation as a component of such ocular and/or dermal diseases and conditions, with cyclosporine derivatives.
  • the present invention relates to a method for the treatment of allergic conjunctivitis, aqueous deficient dry-eye state, phacoanaphylaxis endophthalmitis and uveitis using certain novel cyclosporine derivatives.
  • Inflammation is the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue.
  • Inflammation can be classified as either acute or chronic.
  • Acute inflammation is the initial response of the body to harmful stimuli and is achieved by the increased movement of plasma and leukocytes from the blood into the injured tissues.
  • a cascade of biochemical events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells within the injured tissue.
  • Prolonged inflammation known as chronic inflammation, leads to a progressive shift in the type of cells which are present at the site of inflammation and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process.
  • Acute inflammation is a short-term process which is characterized by the classic signs of inflammation—swelling, redness, pain, heat, and loss of function—due to the infiltration of the tissues by plasma and leukocytes. It occurs as long as the injurious stimulus is present and ceases once the stimulus has been removed, broken down, or walled off by scarring.
  • the process of acute inflammation is initiated by the blood vessels local to the injured tissue, which alter to allow the exudation of plasma proteins and leukocytes into the surrounding tissue.
  • the increased flow of fluid into the tissue causes the characteristic swelling associated with inflammation since the lymphatic system doesn't have the capacity to compensate for it, and the increased blood flow to the area causes the reddened color and increased heat.
  • the blood vessels also alter to permit the extravagation of leukocytes through the endothelium and basement membrane constituting the blood vessel.
  • the cells migrate along a chemotactic gradient to reach the site of injury, where they can attempt to remove the stimulus and repair the tissue.
  • biochemical cascade systems consisting of chemicals known as plasma-derived inflammatory mediators, act in parallel to propagate and mature the inflammatory response.
  • these include the complement system, coagulation system and fibrinolysis system.
  • Chronic inflammation is a pathological condition characterized by concurrent active inflammation, tissue destruction, and attempts at repair. Chronic inflammation is not characterized by the classic signs of acute inflammation listed above. Instead, chronically inflamed tissue is characterized by the infiltration of mononuclear immune cells (monocytes, macrophages, lymphocytes, and plasma cells), tissue destruction, and attempts at healing, which include angiogenesis and fibrosis.
  • mononuclear immune cells mononuclear immune cells (monocytes, macrophages, lymphocytes, and plasma cells
  • tissue destruction include angiogenesis and fibrosis.
  • Endogenous causes include persistent acute inflammation. Exogenous causes are varied and include bacterial infection, prolonged exposure to chemical agents such as silica, tobacco smoke, or autoimmune reactions such as rheumatoid arthritis.
  • the exudative component involves the movement of plasma fluid, containing important proteins such as fibrin and immunoglobulins (antibodies), into inflamed tissue. This movement is achieved by the chemically-induced dilation and increased permeability of blood vessels, which results in a net loss of blood plasma. The increased collection of fluid into the tissue causes edema.
  • Acute inflammation is characterised by marked vascular changes, including vasodilation, increased permeability, and the slowing of blood flow, which are induced by the actions of various inflammatory mediators.
  • Vasodilation occurs first at the arteriole level, progressing to the capillary level, and brings about a net increase in the amount of blood present, causing the redness and heat of inflammation.
  • Increased permeability of the vessels results in the movement of plasma into the tissues, with resultant stasis due to the increase in the concentration of the cells within blood—a condition characterized by enlarged vessels packed with cells.
  • Stasis allows leukocytes to marginate along the endothelium, a process critical to their recruitment into the tissues. Normal flowing blood prevents this, as the shearing force along the periphery of the vessels moves cells in the blood into the middle of the vessel.
  • Abnormalities associated with inflammation comprise a large, unrelated group of disorders which underly a variety of human diseases.
  • the immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.
  • Non-immune diseases with aetiological origins in inflammatory processes are thought to include cancer, atherosclerosis, and ischemic heart disease.
  • disorders associated with inflammation include:
  • the inflammatory response must be actively terminated when no longer needed to prevent unnecessary damage to tissues. Failure to do so results in chronic inflammation, cellular destruction, and attempts to heal the inflamed tissue.
  • One intrinsic mechanism employed to terminate inflammation is the short half-life of inflammatory mediators in vivo. They have a limited time frame to affect their target before breaking down into non-functional components, therefore constant inflammatory stimulation is needed to propagate their effects.
  • Specific diseases and conditions of the eye having an inflammatory component include allergic conjunctivitis, phacoanaphylactic endophthalmitis and uveitis. These diseases and conditions can be located throughout the eye, in both the posterior and anterior chambers of the eye as well as in the vitreous body.
  • Uveitis the inflammation of the uvea, is responsible for about 10% of the visual impairment in the United States.
  • Phacoanaphylactic endophthalmitis is a human autoimmune disease.
  • Panuveitis refers to inflammation of the entire uveal (vascular) layer of the eye.
  • Posterior uveitis generally refers to chorioentinitis
  • anterior uveitis refers to iridocyclitis.
  • the inflammatory products i.e. cells, fibrins, excess proteins
  • Uveitis may occur following surgical or traumatic injury to the eye; as a component of an autoimmune disorder, i.e.
  • rheumatoid arthritis Behcet's disease, ankylosing spondylitis, sarcoidosis; as an isolated immune mediated ocular disorder, i.e. pars planitis, iridocyclitis etc., unassociated with known etiologies; and following certain systemic diseases which cause antibody-antigen complexes to be deposited in the uveal tissues. Together these disorders represent the non-infectious uveitities.
  • Cyclosporins have been used to treat inflammatory conditions including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
  • autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
  • Specific auto-immune diseases for which Cyclosporin has been proposed or applied include, autoimmune hematological disorder (including e.g.
  • hemolytic anaemia aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopaenia
  • systemic lupus erythematosus poly-chondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g.
  • ulcerative colitis and Crohn's disease endocrine opthalmopathy
  • Graves disease sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type 1), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthirits and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy).
  • nephrotic syndrome e.g. including idiopathic nephrotic syndrome or minimal change nephropathy.
  • Such compounds include the methylthio-substituted cyclosporin A and other alkylthio-substituted cyclosporin A derivatives described in PCT application Nos. 98-379455, 98-379456 and 98-379457, which have been found to be active against certain retroviruses, especially AIDS (acquired immunodeficiency syndrome) and ARC (AIDS-related complex) when administered orally, parenterally, rectally or by inhalation.
  • AIDS abred immunodeficiency syndrome
  • ARC AIDS-related complex
  • these compounds have generally been found to have only a very weak immunosuppressant action, and to show anti-retroviral activity at non-cytotoxic and non-cytostatic concentrations.
  • the present invention provides a method for treating an inflammatory disease, disorder or condition of a mammal, e.g. a human, such as an inflammatory disease, disorder or condition of the eye, for example, allergic conjunctivitis, uveitis, or phacoanaphylactic endophthalmitis, comprising the step of administering to a patient in need thereof, including topically or systemically administering to the eye of such patient, a therapeutically effective amount of a compound selected from the group consisting of cyclosporin A derivatives of the formula described below.
  • the present invention preferably provides a method for treating a disorder or condition of the eye, with a therapeutically effective amount of a compound selected from the group consisting of cyclosporin A derivatives.
  • the cyclosporin A derivatives utilized in the method(s) of the present invention are represented by the formula
  • R 1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, e.g. a C 2 to C 6 polymethylene linkage, or a polyalkenylene linkage, e.g. a C 3 to C 6 alkenylenyl linkage, and R is hydrogen or a unsubstituted or substituted hydrocarbyl group.
  • R is a nitrogen-containing hydrocarbyl group, e.g. a poly nitrogen-containing hydrocarbyl group, having 2 or 3 nitrogen atoms, i.e. an amidine or guanidine-containing hydrocarbyl radical.
  • R may be selected from the group consisting of radicals of the following formulae: R is —N ⁇ C(NR 3 R 4 )(NR 5 R 6 ) or
  • —NR 7 [(NR 3 R 4 )C ⁇ NR 5 ], i.e. guanidines or —N ⁇ C(R 8 )(NR 9 R 10 ), i.e. amidines, wherein R 3 -R 10 is H, Alk, Ar or (CH 2 )nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R 3 and R 4 , or R 4 and R 5 , or R 5 and R 7 , or R 3 and R 7 , or R 9 and R 10 , or R 8 and R 9 , together, may be —(CH 2 ) x —, wherein x is an integer of from 2 to 5, e.g. CH 2 —CH 2 — or —CH 2 —CH 2 —CH 2 —.
  • R 2 may be selected from the group consisting of hydroxyl, lower alkyl and hydroxyl-substituted lower alkyl.
  • R 1 may be —S(CH 2 ) 2 N ⁇ C(NH 2 ) 2 and R 2 may be —CH 2 CH(CH 3 ) 2 ,
  • the present invention provides a method for the treatment of inflammatory diseases and conditions, including diseases and conditions of the eye, having an inflammatory component associated therewith, e.g. by topical application to the affected eye, of a cyclosporin derivative, represented by the formula below
  • R 1 and R 2 are defined above.
  • R 1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, e.g. a C 2 to C 6 polymethylene linkage, or a polyalkenylene linkage, e.g. a C 3 to C 6 alkenylenyl linkage and R 2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl.
  • R is —N ⁇ C(NR 3 R 4 )(NR 5 R 6 ) or —NR 7 [(NR 3 R 4 )C ⁇ NR 5 ], i.e. a guanidine or —N ⁇ C(R 8 )(NR 9 R 10 ), i.e.
  • R 3 -R 10 is H, Alk, Ar or (CH 2 )nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R 3 and R 4 , or R 4 and R 5 , or R 5 and R 7 , or R 3 and R 7 , or R 9 and R 10 , or R 8 and R 9 , together, may be —(CH 2 ) x —, wherein x is an integer of from 2 to 5, e.g. —CH 2 —CH 2 — or —CH 2 —CH 2 —CH 2 —.
  • R 1 is a hydrogen atom or a radical of formula (Ia):
  • Alk-R 11 represents a methyl radical, or alternatively
  • Alk represents a C 2 -C 6 straight chain or branched alkylene radical or a C 3 -C 6 cycloalkylene radical
  • R 11 represents
  • R 12 and R 13 which are identical or different, represent a hydrogen atom or a phenyl, alkyl, C 2 -C 4 alkenyl or C 3 -C 6 cycloalkyl radical, said radical optionally substituted with selected from a halogen atom, an alkyloxy, alkyloxycarbonyl, amino, alkylamino and dialkylamino radical; or
  • R 12 and R 13 represent a benzyl or saturated or unsaturated heterocycylic radical, said heterocycylic radical containing from 5 to 6 ring members and from 1 to 3 heteroatoms;
  • R 12 and R 13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 6-membered heterocycle, which heterocycle having an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or R 1 is a radical of the formula (Ib): —N(R 14 )—(CH 2 ) n —NR 12 R 13 in which R 12 and R 13 are as defined above, R 14 represents a hydrogen atom or an alkyl radical and n is an integer ranging from 2 to 4,
  • R 2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl,
  • R 1 is a hydrogen atom
  • R 2 is not an alkyl butyl? radical
  • the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof.
  • trans butene moiety which is normally present in the 1-position of cyclosporine A, may be replaced with R 15 wherein R 15 represents a radical of formula
  • R 16 represents an alkylthio, aminoalkylthio, alkylaminoalkylthio, dialkylaminoalkylthio, pyrimidinylthio, thiazolylthio, N-alkylimidazolylthio, hydroxyalkylphenylthio, hydroxyalkylphenyloxy, nitrophenylamino or 2-oxopyrimidin-1-yl radical and R 17 represents an alkyl radical.
  • compositions for topical application in the treatment of an inflammatory disease, disorder or condition of a mammal e.g. a human, such as an inflammatory disease, disorder or condition of the eye, for example, allergic conjunctivitis, uveitis, or phacoanaphylactic endophthalmitis, comprising the step of administering to a patient in need thereof, including topically or systemically administering to the eye of such patient, a therapeutically effective amount of a compound selected from the group consisting of the above cyclosporin A derivatives.
  • Alkyl refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon.
  • the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, most preferably 1 to 4 carbons.
  • Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like.
  • the alkyl group may be optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, ⁇ O, ⁇ S, NO 2 , halogen, dimethyl amino and SH.
  • Alkenyl refers to a straight-chain, branched or cyclic unsaturated hydrocarbon group containing at least one carbon—carbon double bond.
  • the alkenyl group has 2 to 12 carbons. More preferably it is a lower alkenyl of from 2 to 7 carbons, most preferably 2 to 4 carbons.
  • the alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, O, S, NO 2 , halogen, dimethyl amino and SH.
  • Aryl refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups.
  • the aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, SH, OH, NO 2 , amine, thioether, cyano, alkoxy, alkyl, and amino.
  • Alkaryl refers to an alkyl that is covalently joined to an aryl group.
  • the alkyl is a lower alkyl.
  • Alkoxy refers to an “O-alkyl” group.
  • tBoc refers to a t-butyloxycarbonyl protecting group.
  • Carbocyclic aryl refers to an aryl group wherein the ring atoms are carbon.
  • Heterocyclic aryl refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen.
  • cyclosporine A derivatives used in the method of this invention are prepared as follows:
  • R 4 , R 5 and R 6 are hydrogen and R 7 is hydrogen, alkyl, substituted alkyl or aryl may be prepared by reaction of a compound of formula (I) where X is a leaving group and P is a protecting group with a compound of formula (II) in a suitable solvent such as methanol to afford compounds of formula (III).
  • a suitable solvent such as methanol
  • Protecting groups P are preferably tertiary butyloxycarbonyl groups (tBoc) groups.
  • Protecting groups P are preferably tertiary butyloxycarbonyl groups (tBoc) groups.
  • R 11 is preferably lower alkyl and typical examples of compound (VIII) are Dimethylformamide dimethylacetal (DMF.DMA) and Dimethylacetamide dimethylacetal (DMA.DMA).
  • DMF.DMA Dimethylformamide dimethylacetal
  • DMA.DMA Dimethylacetamide dimethylacetal
  • Compound (II) was analysed by 1 H, 13 C, DEPT NMR and subsequently by a series of 2-D NMR experiments, HMQC, HMBC and DEPT-HMQC.
  • HMQC Hetronuclear Multiple Quantum Coherence
  • HMBC Hetronuclear Multiple Bond Correlation
  • DEPT-HSQC edited Hetronuclear Single Quantum Coherence
  • the cyclosporin A derivatives may be applied, e.g. to an affected eye, in any efficacious concentration.
  • the composition may comprise, 0.01 to saturation (e.g. greater than 20 weight percent) of said cyclosporin A derivative in a pharmaceutically acceptable excipient. From 0.01 to 50 weight percent, preferably from 0.1 to 20 weight percent, of cyclosporin A derivatives in a pharmaceutically acceptable excipient may be used.
  • pharmaceutically acceptable excipients are, for example, animal oil, vegetable oil, an appropriate organic or aqueous solvent, an artificial tear solution, a natural or synthetic polymer, or an appropriate membrane to encapsulate the cyclosporin A derivative.
  • these pharmaceutically acceptable excipients are olive oil, arachis oil, castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, chremophor, Miglyol 182 (commercially available from Dynamit Nobel Kay-Fries Chemical Company, Mont Vale, N.J.), an alcohol (e.g. ethanol, n-propyl alcohol, or iso-propyl alcohol), liposomes or liposome-like products or a silicone fluid.
  • Preferred excipients are dimethyl sulphoxide and olive oil. Mixtures of at least two of any suitable excipients may be used.
  • artificial tear excipients which can be advantageously used in the practice of this invention are isotonic sodium chloride, cellulose ethers such as hydroxypropylmethylcellulose and hydroxyethylcellulose, polyvinyl alcohol and available artificial tea solutions.
  • An example of a useful polymeric excipient is a polyoxyethylated castor oil.
  • Examples of pharmaceutically acceptable membranes which can be advantageously used in the practice of this invention are microdone, an artificial lipid membrane, polyvinyl alcohol, or methylcellulose.
  • the cyclosporin A derivatives are advantageously administered topically as an ophthalmic drop (solution or suspension) or ophthalmic ointment containing an effective amount of the derivative. Concentrations of 0.01 to 50 weight percent, preferably 0.1 to 20 weight percent, of the cyclosporin A derivatives are used in the practice of the present invention.
  • At least one of the cyclosporin A derivatives is administered topically in any quantity required to provide the degree of treatment needed.
  • any quantity required to provide the degree of treatment needed for example, 5 microliters to 1 milliliter of a solution, suspension, or ointment containing an effective amount of the cyclosporin A derivative, such as 0.01 to 50 weight percent, preferably 0.1 to 20 weight percent, of the cyclosporin A derivative is advantageously used.
  • the method of the present invention is useful in that it can locally prevent activation of a presystemic response.
  • Topical administration of the cyclosporin A derivatives to a patient's tear deficient eye increases tear production in the eye.
  • such treatment further serves to correct corneal and conjunctival disorders exacerbated by tear deficiency and KCS, such as corneal scarring, corneal ulceration, inflammation of the cornea or conjunctiva, filamentary keratisis, mucopurulent discharge and vascularization of the cornea.
  • the cyclosporin A derivatives directly decrease the immune response and granulation and neovascularization.
  • This example compares the relative potency of the cyclosporine analogues utilized in the method of the present invention with cyclosporine A in modulating Jurkat T cell functions.
  • the percentage (%) of apoptic T cells is determined @ 10 uM compound concentration for 24 hours of incubation period.
  • the percentage (%) inhibition in IL-2 production is determined 10 uM compound concentration for 24 hours of incubation period.
  • Cyclosporin A 100 CsA-A 1 100 CsA-A2 82 CsA-A3 28 CsA-A4 19 CsA-A5 36 CsA-A6 4
  • the compound CsA-A1 shows equivalent effectiveness as compared to cyclosporine A in this experiment.
  • This example compares the relative potency of CsA-A1, the most preferred cyclosporine A derivative utilized in the method of the present invention with cyclosporine A in an in-vivo modal of ocular inflammation.
  • Rats were injected in the foot pad LPS (100 ug/rat.) 5 rats were treated in each of the following groups.
  • the topical vehicle was the Restasis vehicle.
  • the systemic vehicle was:
  • FIG. 1.A As can be observed in FIGS. 1 A through E CsA-A1 showed a similar potency to cyclosporine A in inhibiting acute intraocular inflammation when applied topically and/or systemically in this experiment.
  • This example compares the relative potency of CsA-A1, the most preferred cyclosporine A derivative utilized in the method of the present invention with cyclosporine A in an in-vivo modal of ocular inflammation.
  • Rat EAU Model Chronic Intraocular Inflammation Rats were immunized with R16 (RIBP immunogenic peptide, 100 ug/rat. The rats were then fitted with Alzet Pump to deliver 5 mg/kg/day of the test sample, below, or injected intraperitoneal with 10 mg/kg, q.d. of the test sample. 5 rats were treated in each of the following groups. The vehicle was
  • FIG. 2 The results are shown in FIG. 2. s can be observed in FIGS. 2 A through 2K E CsA-A1 showed a similar potency to cyclosporine A in inhibiting acute intraocular inflammation when applied by intraperitoneal injection in this experiment. However, as a result of its lower solubility in the vehicle, it appeared to be less effective when applied by the Alzet Pump.
  • the Rat EAU model is indicative of autoimmune-mediated inflammatory conditions. Indeed, uveitis may precede, accompany or develop following the onset of many systemic autoimmune diseases including juvenile rheumatoid arthritis (RA), psoriatic arthritis, multiple sclerosis (MS), inflammatory bowel disease and systemic lupus erythematosus.
  • RA juvenile rheumatoid arthritis
  • MS multiple sclerosis
  • inflammatory bowel disease and systemic lupus erythematosus.
  • the etiology of these chronic inflammatory conditions is not well understood; however, evidence suggests that autoreactive T cells and antibodies recognizing self-antigens localized within affected tissues drives the chronic inflammatory response, e.g. uveal and/or retinal antigens, myelin proteins within central nervous system or components of cartilage in patients with uveitis, MS and RA respectively.
  • novel cyclosporine derivatives that may be used in the method of the present invention further include 3-substituted iminoalkylthio cyclosporin A derivatives, preferably 3-substituted diaminoiminoalkylthio cyclosporin A derivatives, e.g.
  • the invention may be summarized as follows.
  • a method for the treatment of an inflammatory disease, disorder or condition of a mammal comprising the step of administering to a patient in need thereof, a therapeutically effective amount of a cyclosporin A derivative selected from the group consisting of compounds represented by the formula:
  • R 1 is S-Alk-R wherein Alk is an alkylene linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
  • Alk is a methylene or a C 3 to C 6 alkenylenyl linkage.
  • R is —N ⁇ C(NR 3 R 4 )(NR 5 R 6 ) or —NR 7 C(NR 3 )(C ⁇ NR 5 ), wherein R 3 -R 7 is H, Alk, Ar or (CH 2 )nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R 3 and R 4 or R 4 and R 5 or R 5 and R 7 or R 3 and R 7 , together may be —CH 2 —CH 2 — or —CH 2 —CH 2 —CH 2 —.
  • cyclosporine A derivative is selected from the group consisting of ((R)-(diamino)iminoalkyllthio-Sar) 3 -(4′-hydroxy-MeLeu) 4 cyclosporin A derivatives, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar) 3 -(4′-hydroxy-MeLeu) 4 -cyclosporin A, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar) 3 -cyclosporin A derivatives and ((R)-(diamino)iminoalkylthio-Sar) 3 -cyclosporin A derivatives.
  • cyclosporine A derivative is selected from the group of compounds according to 1 wherein R 1 is —S(CH 2 ) 2 N ⁇ C(NH 2 ) 2 and R 2 is —CH 2 CH(CH 3 ) 2 , —CH 2 C(OH)(CH 3 ) 2 , —CH(CH 3 ) 2 or —CH(CH 3 )CH 2 CH 3 .
  • the pharmaceutically acceptable excipient is selected from the group consisting of olive oil, arachis oil, castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, silicone fluid and mixtures thereof.
  • R 1 is a hydrogen atom or a radical of formula (Ia):
  • Alk-R 11 represents a methyl radical, or alternatively
  • Alk represents a C 2 -C 6 straight chain or branched alkylene radical or a C 3 -C 6 cycloalkylene radical
  • R 11 represents
  • R 12 and R 13 which are identical or different, represent a hydrogen atom or a phenyl, alkyl, C 2 -C 4 alkenyl or C 3 -C 6 cycloalkyl radical, said radical optionally substituted with selected from a halogen atom, an alkyloxy, alkyloxycarbonyl, amino, alkylamino and dialkylamino radical; or
  • R 12 and R 13 represent a benzyl or saturated or unsaturated heterocycylic radical, said heterocycylic radical containing from 5 to 6 ring members and from 1 to 3 heteroatoms;
  • R 12 and R 13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 6-membered heterocycle, which heterocycle having an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or R 1 is a radical of the formula (Ib): —N(R 14 )—(CH 2 ) n —NR 12 R 13 in which R 12 and R 13 are as defined above, R 14 represents a hydrogen atom or an alkyl radical and n is an integer ranging from 2 to 4,
  • R 2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl,
  • R 1 is a hydrogen atom
  • R 2 is not an alkyl butyl? radical
  • the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof.
  • R 16 represents an alkylthio, aminoalkylthio, alkylaminoalkylthio, dialkylaminoalkylthio, pyrimidinylthio, thiazolylthio, N-alkylimidazolylthio, hydroxyalkylphenylthio, hydroxyalkylphenyloxy, nitrophenylamino or 2-oxopyrimidin-1-yl radical and R 17 represents an alkyl radical.
  • R 12 and R 13 which are identical or different, represent a hydrogen atom or an alkyl, C 2 -C 4 alkenyl, C 3 -C 6 cycloalkyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom, or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represent a benzyl or heterocyclyl radical, wherein said heterocyclyl radical may be saturated or unsaturated and contains 5 or 6 ring members and from 1 to 3 heteroatoms; or in which R 12 and R 13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl
  • R. 14 represents a hydrogen atom or an alkyl radical, and n is an integer from 2 to 4;
  • alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms;
  • Alk represents a C 3 -C 6 straight chain or branched alkylene radical
  • R represents
  • R 12 and R 13 which are identical or different, represent a hydrogen atom or an alkyl, C 3-4 alkenyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represents a benzyl radical; or in which R 12 and R 13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl radical;
  • Alk represents a C 2-6 straight chain or branched alkylene radical
  • R represents a hydroxyl radical, or an —NR 12 R 13 radical in which R 12 and R 13 , which are identical or different, represent a hydrogen atom or an alkyl, allyl, phenyl or benzyl radical; or in which R 12 and R 13 form, together with the nitrogen atom to which they are attached, a heterocycle selected from azetidinyl, piperidyl, piperazinyl, N-methylpiperazinyl, N-phenylpiperazinyl, N-benzylpiperazinyl, morpholino, tetrahydropyridyl, methyltetrahydropyridyl and phenyltetrahydropyridyl;
  • cyclosporine A derivative is selected from the group consisting of [(R)-2-(N,N-dimethyl-amino)ethylthio-Sar] 3 -[4′-hydroxy-MeLeu] 4 -cyclosporin A,
  • a method of treating inflammatory diseases selected from the group consisting of ocular inflammatory diseases, dermal inflammatory diseases, inflammatory rheumatic diseases, inflammatory bowel disease, neuroinflammatory diseases and autoimmune hematological diseases and disorders wherein said cyclosporine A derivative is selected from the group consisting of compounds represented by the formula:
  • R 1 is S-Alk-R wherein Alk is an alkylene or alkylenyl linkage, R is
  • R 3 -R 7 10 is H, Alk, Ar or (CH 2 )nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R 3 and R 4 , or R 4 and R 5 , or R 5 and R 7 , or R 3 and R 7 , or R 9 and R 10 , or R 8 and R 9 , together, may be —(CH 2 ) x —, wherein x is an integer of from 2 to 5 and R 2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl-substituted lower alkyl.
  • R is —N ⁇ C(NR 3 R 4 )(NR 5 R 6 ) or —NR 7 C(NR 3 )(C ⁇ NR 5 ), wherein R 3 -R 7 is H, Alk, Ar or (CH 2 )nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R 3 and R 4 or R 4 and R 5 or R 5 and R 7 or R 3 and R 7 , together may be —CH 2 —CH 2 — or —CH 2 —CH 2 —CH 2 —.
  • cyclosporine A derivative is selected from the group consisting of ((R)-(diamino)iminoalkyllthio-Sar) 3 -(4′-hydroxy-MeLeu) 4 cyclosporin A derivatives, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar) 3 -(4′-hydroxy-MeLeu) 4 -cyclosporin A, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar) 3 -cyclosporin A derivatives and ((R)-(diamino)iminoalkylthio-Sar) 3 -cyclosporin A derivatives
  • Alk-R 11 represents a methyl radical, or alternatively
  • Alk represents a C 2 -C 6 straight chain or branched alkylene radical or a C 3 -C 6 cycloalkylene radical
  • R 11 represents
  • R 12 and R 13 which are identical or different, represent a hydrogen atom or a phenyl, alkyl, C 2 -C 4 alkenyl or C 3 -C 6 cycloalkyl radical, said radical optionally substituted with selected from a halogen atom, an alkyloxy, alkyloxycarbonyl, amino, alkylamino and dialkylamino radical; or
  • R 12 and R 13 represent a benzyl or saturated or unsaturated heterocycylic radical, said heterocycylic radical containing from 5 to 6 ring members and from 1 to 3 heteroatoms;
  • R 12 and R 13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 6-membered heterocycle, which heterocycle having an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or R 1 is a radical of the formula (Ib): —N(R 14 )—(CH 2 ) n —NR 12 R 13 in which R 12 and R 13 are as defined above, R 14 represents a hydrogen atom or an alkyl radical and n is an integer ranging from 2 to 4,
  • R 2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl,
  • R 1 is a hydrogen atom
  • R 2 is not an alkyl butyl? radical
  • the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof.
  • R 16 represents an alkylthio, aminoalkylthio, alkylaminoalkylthio, dialkylaminoalkylthio, pyrimidinylthio, thiazolylthio, N-alkylimidazolylthio, hydroxyalkylphenylthio, hydroxyalkylphenyloxy, nitrophenylamino or 2-oxopyrimidin-1-yl radical and R 17 represents an alkyl radical.
  • R 12 and R 13 which are identical or different, represent a hydrogen atom or an alkyl, C 2 -C 4 alkenyl, C 3 -C 6 cycloalkyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom, or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represent a benzyl or heterocyclyl radical, wherein said heterocyclyl radical may be saturated or unsaturated and contains 5 or 6 ring members and from 1 to 3 heteroatoms; or in which R 12 and R 13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl
  • R. 14 represents a hydrogen atom or an alkyl radical, and n is an integer from 2 to 4;
  • alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms;
  • Alk represents a C 3 -C 6 straight chain or branched alkylene radical
  • R represents a hydroxyl radical, or an —NR 12 R 13 radical in which R 12 and R 13 , which are identical or different, represent a hydrogen atom or an alkyl, C 3-4 alkenyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represents a benzyl radical; or in which R 12 and R 13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl radical;
  • Alk represents a C 2-6 straight chain or branched alkylene radical
  • R represents a hydroxyl radical, or an —NR 12 R 13 radical in which R 12 and R 13 , which are identical or different, represent a hydrogen atom or an alkyl, allyl, phenyl or benzyl radical; or in which R 12 and R 13 form, together with the nitrogen atom to which they are attached, a heterocycle selected from azetidinyl, piperidyl, piperazinyl, N-methylpiperazinyl, N-phenylpiperazinyl, N-benzylpiperazinyl, morpholino, tetrahydropyridyl, methyltetrahydropyridyl and phenyltetrahydropyridyl;
  • ocular autoimmune hematological disorder is hemolytic anaemia, aplastic anaemia, pure red cell anaemia, or idiopathic thrombocytopaenia.

Abstract

The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula:
Figure US20140005124A1-20140102-C00001
wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.

Description

    CROSS-REFERENCE
  • This is a continuation application of U.S. patent application Ser. No. 12/785,133, filed on May 21, 2010 (now U.S. Pat. No. 8,524,671), which claims priority from U.S. Patent Application No. 61/181,382, filed on May 27, 2009. The entire contents of all of the foregoing are incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The invention relates to a method of treating inflammatory, including ocular and/or dermal, diseases and conditions having inflammation as a component of such ocular and/or dermal diseases and conditions, with cyclosporine derivatives. In particular, the present invention relates to a method for the treatment of allergic conjunctivitis, aqueous deficient dry-eye state, phacoanaphylaxis endophthalmitis and uveitis using certain novel cyclosporine derivatives.
  • 2. Description of the Related Art
  • Inflammation is the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue.
  • In the absence of inflammation, wounds and infections would never heal and progressive destruction of the tissue would compromise the survival of the organism. However, inflammation which runs unchecked can also lead to a host of diseases, such as hay fever, atherosclerosis, and rheumatoid arthritis. It is for this reason that inflammation is normally tightly regulated by the body.
  • Inflammation can be classified as either acute or chronic. Acute inflammation is the initial response of the body to harmful stimuli and is achieved by the increased movement of plasma and leukocytes from the blood into the injured tissues. A cascade of biochemical events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells within the injured tissue. Prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells which are present at the site of inflammation and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process.
  • Acute inflammation is a short-term process which is characterized by the classic signs of inflammation—swelling, redness, pain, heat, and loss of function—due to the infiltration of the tissues by plasma and leukocytes. It occurs as long as the injurious stimulus is present and ceases once the stimulus has been removed, broken down, or walled off by scarring.
  • The process of acute inflammation is initiated by the blood vessels local to the injured tissue, which alter to allow the exudation of plasma proteins and leukocytes into the surrounding tissue. The increased flow of fluid into the tissue causes the characteristic swelling associated with inflammation since the lymphatic system doesn't have the capacity to compensate for it, and the increased blood flow to the area causes the reddened color and increased heat. The blood vessels also alter to permit the extravagation of leukocytes through the endothelium and basement membrane constituting the blood vessel. Once in the tissue, the cells migrate along a chemotactic gradient to reach the site of injury, where they can attempt to remove the stimulus and repair the tissue.
  • Meanwhile, several biochemical cascade systems, consisting of chemicals known as plasma-derived inflammatory mediators, act in parallel to propagate and mature the inflammatory response. These include the complement system, coagulation system and fibrinolysis system.
  • Finally, down-regulation of the inflammatory response concludes acute inflammation. Removal of the injurious stimuli halts the response of the inflammatory mechanisms, which require constant stimulation to propagate the process. Additionally, many inflammatory mediators have short half lives and are quickly degraded in the tissue, helping to quickly cease the inflammatory response once the stimulus has been removed.
  • Chronic inflammation is a pathological condition characterized by concurrent active inflammation, tissue destruction, and attempts at repair. Chronic inflammation is not characterized by the classic signs of acute inflammation listed above. Instead, chronically inflamed tissue is characterized by the infiltration of mononuclear immune cells (monocytes, macrophages, lymphocytes, and plasma cells), tissue destruction, and attempts at healing, which include angiogenesis and fibrosis.
  • Endogenous causes include persistent acute inflammation. Exogenous causes are varied and include bacterial infection, prolonged exposure to chemical agents such as silica, tobacco smoke, or autoimmune reactions such as rheumatoid arthritis.
  • In acute inflammation, removal of the stimulus halts the recruitment of monocytes (which become macrophages under appropriate activation) into the inflamed tissue, and existing macrophages exit the tissue via lymphatics. However in chronically inflamed tissue the stimulus is persistent, and therefore recruitment of monocytes is maintained, existing macrophages are tethered in place, and proliferation of macrophages is stimulated.
  • The exudative component involves the movement of plasma fluid, containing important proteins such as fibrin and immunoglobulins (antibodies), into inflamed tissue. This movement is achieved by the chemically-induced dilation and increased permeability of blood vessels, which results in a net loss of blood plasma. The increased collection of fluid into the tissue causes edema.
  • Acute inflammation is characterised by marked vascular changes, including vasodilation, increased permeability, and the slowing of blood flow, which are induced by the actions of various inflammatory mediators. Vasodilation occurs first at the arteriole level, progressing to the capillary level, and brings about a net increase in the amount of blood present, causing the redness and heat of inflammation. Increased permeability of the vessels results in the movement of plasma into the tissues, with resultant stasis due to the increase in the concentration of the cells within blood—a condition characterized by enlarged vessels packed with cells. Stasis allows leukocytes to marginate along the endothelium, a process critical to their recruitment into the tissues. Normal flowing blood prevents this, as the shearing force along the periphery of the vessels moves cells in the blood into the middle of the vessel.
  • Abnormalities associated with inflammation comprise a large, unrelated group of disorders which underly a variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. Non-immune diseases with aetiological origins in inflammatory processes are thought to include cancer, atherosclerosis, and ischemic heart disease.
  • A large variety of proteins are involved in inflammation, and any one of them is open to a genetic mutation which impairs or otherwise deregulates the normal function and expression of that protein.
  • Examples of disorders associated with inflammation include:
      • Asthma
      • Autoimmune diseases
      • Chronic inflammation
      • Chronic prostatitis
      • Glomerulonephritis
      • Hypersensitivities
      • Inflammatory bowel diseases
      • Pelvic inflammatory disease
      • Reperfusion injury
      • Rheumatoid arthritis
      • Transplant rejection
      • Vasculitis
  • The inflammatory response must be actively terminated when no longer needed to prevent unnecessary damage to tissues. Failure to do so results in chronic inflammation, cellular destruction, and attempts to heal the inflamed tissue. One intrinsic mechanism employed to terminate inflammation is the short half-life of inflammatory mediators in vivo. They have a limited time frame to affect their target before breaking down into non-functional components, therefore constant inflammatory stimulation is needed to propagate their effects.
  • Active mechanisms which serve to terminate inflammation include
      • TGF-β from macrophages
      • Anti-inflammatory lipoxins
      • Inhibition of pro-inflammatory molecules, such as leukotrienes
  • Specific diseases and conditions of the eye having an inflammatory component include allergic conjunctivitis, phacoanaphylactic endophthalmitis and uveitis. These diseases and conditions can be located throughout the eye, in both the posterior and anterior chambers of the eye as well as in the vitreous body.
  • Uveitis, the inflammation of the uvea, is responsible for about 10% of the visual impairment in the United States. Phacoanaphylactic endophthalmitis is a human autoimmune disease.
  • Panuveitis refers to inflammation of the entire uveal (vascular) layer of the eye. Posterior uveitis generally refers to chorioentinitis, and anterior uveitis refers to iridocyclitis. The inflammatory products (i.e. cells, fibrins, excess proteins) of these inflammations are commonly found in the fluid spaces if the eye, i.e. anterior chamber, posterior chamber and vitreous space as well as infiltrating the tissue intimately involved in the inflammatory response. Uveitis may occur following surgical or traumatic injury to the eye; as a component of an autoimmune disorder, i.e. rheumatoid arthritis, Behcet's disease, ankylosing spondylitis, sarcoidosis; as an isolated immune mediated ocular disorder, i.e. pars planitis, iridocyclitis etc., unassociated with known etiologies; and following certain systemic diseases which cause antibody-antigen complexes to be deposited in the uveal tissues. Together these disorders represent the non-infectious uveitities.
  • Cyclosporins have been used to treat inflammatory conditions including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific auto-immune diseases for which Cyclosporin has been proposed or applied include, autoimmune hematological disorder (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopaenia), systemic lupus erythematosus, poly-chondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease) endocrine opthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type 1), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthirits and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy). (See U.S. Pat. No. 6,346,511.)
  • Thus, it will be understood that it is desirable to develop compounds that are useful in treating inflammatory diseases and conditions. It has been found that the compounds disclosed herein may be used to treat various inflammatory diseases and conditions.
  • Such compounds include the methylthio-substituted cyclosporin A and other alkylthio-substituted cyclosporin A derivatives described in PCT application Nos. 98-379455, 98-379456 and 98-379457, which have been found to be active against certain retroviruses, especially AIDS (acquired immunodeficiency syndrome) and ARC (AIDS-related complex) when administered orally, parenterally, rectally or by inhalation. In addition, these compounds have generally been found to have only a very weak immunosuppressant action, and to show anti-retroviral activity at non-cytotoxic and non-cytostatic concentrations. These compounds are claimed to have a synergistic action with other agents active against retrovirus (such as inhibitors of reverse transcriptase, protease, integrase, HIV replication and nucleocapside). (See also U.S. Pat. Nos. 5,944,299; 5,977,067; 5,965,527 and 5,948,755)
  • These compounds are also claimed for use in the treatment of ocular diseases and conditions in U.S. Pat. Nos. 6,350,442 and 6,254,860.
  • Thus, it is one object of this invention to treat inflammatory diseases and conditions, including diseases and conditions having inflammation as a component thereof, with cyclosporine derivatives.
  • It is another object of this invention to provide cyclosporine A derivatives to treat ocular diseases and conditions, such as allergic conjunctivitus.
  • It is one object of this invention to treat ocular diseases and conditions, including ocular diseases and conditions having inflammation as a component thereof, with cyclosporine derivatives.
  • It is another object of the invention to treat dermal diseases and conditions, including dermal diseases and conditions having inflammation as a component thereof, with cyclosporine derivatives.
  • It is another object of the invention to treat dermal conditions, such as psoriasis and dermatitis.
  • Other objects of this invention will become apparent from a reading of the present specification.
    • SUMMARY OF THE INVENTION
  • The present invention provides a method for treating an inflammatory disease, disorder or condition of a mammal, e.g. a human, such as an inflammatory disease, disorder or condition of the eye, for example, allergic conjunctivitis, uveitis, or phacoanaphylactic endophthalmitis, comprising the step of administering to a patient in need thereof, including topically or systemically administering to the eye of such patient, a therapeutically effective amount of a compound selected from the group consisting of cyclosporin A derivatives of the formula described below. The present invention preferably provides a method for treating a disorder or condition of the eye, with a therapeutically effective amount of a compound selected from the group consisting of cyclosporin A derivatives. The cyclosporin A derivatives utilized in the method(s) of the present invention are represented by the formula
  • Figure US20140005124A1-20140102-C00002
  • wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, e.g. a C2 to C6 polymethylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage, and R is hydrogen or a unsubstituted or substituted hydrocarbyl group. Preferably, R is a nitrogen-containing hydrocarbyl group, e.g. a poly nitrogen-containing hydrocarbyl group, having 2 or 3 nitrogen atoms, i.e. an amidine or guanidine-containing hydrocarbyl radical. In particular, R may be selected from the group consisting of radicals of the following formulae: R is —N═C(NR3R4)(NR5R6) or
  • —NR7[(NR3R4)C═NR5], i.e. guanidines or —N═C(R8)(NR9R10), i.e. amidines, wherein R3-R10 is H, Alk, Ar or (CH2)nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R3 and R4, or R4 and R5, or R5 and R7, or R3 and R7, or R9 and R10, or R8 and R9, together, may be —(CH2)x—, wherein x is an integer of from 2 to 5, e.g. CH2—CH2— or —CH2—CH2—CH2—.
  • R2 may be selected from the group consisting of hydroxyl, lower alkyl and hydroxyl-substituted lower alkyl.
  • For example, R1 may be —S(CH2)2N═C(NH2)2 and R2 may be —CH2CH(CH3)2,
  • —CH2C(OH)(CH3)2, —CH(CH3)2 or —CH(CH3)CH2CH3.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a method for the treatment of inflammatory diseases and conditions, including diseases and conditions of the eye, having an inflammatory component associated therewith, e.g. by topical application to the affected eye, of a cyclosporin derivative, represented by the formula below
  • Figure US20140005124A1-20140102-C00003
  • wherein R1 and R2 are defined above. In particular R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, e.g. a C2 to C6 polymethylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl.
  • In a first aspect of the invention, R is —N═C(NR3R4)(NR5R6) or —NR7[(NR3R4)C═NR5], i.e. a guanidine or —N═C(R8)(NR9R10), i.e. an amidine wherein R3-R10 is H, Alk, Ar or (CH2)nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R3 and R4, or R4 and R5, or R5 and R7, or R3 and R7, or R9 and R10, or R8 and R9, together, may be —(CH2)x—, wherein x is an integer of from 2 to 5, e.g. —CH2—CH2— or —CH2—CH2—CH2—.
  • In a second aspect of the invention, R1 is a hydrogen atom or a radical of formula (Ia):

  • —S-Alk-R11  (Ia)
  • in which
  • Alk-R11 represents a methyl radical, or alternatively
  • Alk represents a C2-C6 straight chain or branched alkylene radical or a C3-C6 cycloalkylene radical, and
  • R11. represents
  • a hydrogen atom or a hydroxyl, carboxyl or alkyloxycarbonyl radical, or
  • an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or a phenyl, alkyl, C2-C4 alkenyl or C3-C6 cycloalkyl radical, said radical optionally substituted with selected from a halogen atom, an alkyloxy, alkyloxycarbonyl, amino, alkylamino and dialkylamino radical; or
  • R12 and R13 represent a benzyl or saturated or unsaturated heterocycylic radical, said heterocycylic radical containing from 5 to 6 ring members and from 1 to 3 heteroatoms;
  • or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 6-membered heterocycle, which heterocycle having an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or R1 is a radical of the formula (Ib): —N(R14)—(CH2)n—NR12R13 in which R12 and R13 are as defined above, R14 represents a hydrogen atom or an alkyl radical and n is an integer ranging from 2 to 4,
  • and R2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl,
  • with the proviso that, when R1 is a hydrogen atom, then R2 is not an alkyl butyl? radical, and wherein the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof.
  • In the cyclosporine A derivatives of this second aspect of the invention, the trans butene moiety, which is normally present in the 1-position of cyclosporine A, may be replaced with R15 wherein R15 represents a radical of formula
  • —CH2CHCHCH2—R16 (Ic) or —CH2SR17 (Id), wherein R16 represents an alkylthio, aminoalkylthio, alkylaminoalkylthio, dialkylaminoalkylthio, pyrimidinylthio, thiazolylthio, N-alkylimidazolylthio, hydroxyalkylphenylthio, hydroxyalkylphenyloxy, nitrophenylamino or 2-oxopyrimidin-1-yl radical and R17 represents an alkyl radical.
  • This invention also provides pharmaceutical compositions for topical application in the treatment of an inflammatory disease, disorder or condition of a mammal, e.g. a human, such as an inflammatory disease, disorder or condition of the eye, for example, allergic conjunctivitis, uveitis, or phacoanaphylactic endophthalmitis, comprising the step of administering to a patient in need thereof, including topically or systemically administering to the eye of such patient, a therapeutically effective amount of a compound selected from the group consisting of the above cyclosporin A derivatives.
  • For the purpose of describing and claiming the present invention the following terms shall have the following meanings:
  • “Alkyl” refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, most preferably 1 to 4 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, ═O, ═S, NO2, halogen, dimethyl amino and SH.
  • “Alkenyl” refers to a straight-chain, branched or cyclic unsaturated hydrocarbon group containing at least one carbon—carbon double bond. Preferably, the alkenyl group has 2 to 12 carbons. More preferably it is a lower alkenyl of from 2 to 7 carbons, most preferably 2 to 4 carbons. The alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, O, S, NO2, halogen, dimethyl amino and SH.
  • “Aryl” refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups. The aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, SH, OH, NO2, amine, thioether, cyano, alkoxy, alkyl, and amino.
  • “Alkaryl” refers to an alkyl that is covalently joined to an aryl group. Preferably, the alkyl is a lower alkyl.
  • “Alkoxy” refers to an “O-alkyl” group.
  • “tBoc” refers to a t-butyloxycarbonyl protecting group.
  • “Carbocyclic aryl” refers to an aryl group wherein the ring atoms are carbon.
  • “Heterocyclic aryl” refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen.
  • The cyclosporine A derivatives used in the method of this invention are prepared as follows:
  • Compounds where R4, R5 and R6 are hydrogen and R7 is hydrogen, alkyl, substituted alkyl or aryl may be prepared by reaction of a compound of formula (I) where X is a leaving group and P is a protecting group with a compound of formula (II) in a suitable solvent such as methanol to afford compounds of formula (III). For compounds of formula I, typical examples of the protecting group are where X=chlorine, MeS, MeSO2, 1-imidazolyl and especially 1-pyrazolyl.
  • Protecting groups P are preferably tertiary butyloxycarbonyl groups (tBoc) groups.
  • Figure US20140005124A1-20140102-C00004
  • Compounds of formula (III) may be de-protected under a variety of conditions to provide compounds of formula (IV). For example, when P=tertiary butyloxycarbonyl groups (tBoc), this may be removed under acidic conditions using acids such as methanesulphonic acid.
  • Compounds of formula (V) where R7 is hydrogen, alkyl, substituted alkyl or aryl; R3 is alkyl, substituted alkyl or aryl, may be prepared by reaction of a compound of formula (VI) where X is a leaving group and P is a protecting group with a compound of formula (II) in a suitable solvent such as methanol to afford compounds of formula (VII).
  • For compounds of formula (VI), typical examples of the protecting group are where X=chlorine, MeS, MeSO2, 1-imidazolyl and especially 1-pyrazolyl. Protecting groups P are preferably tertiary butyloxycarbonyl groups (tBoc) groups.
  • Figure US20140005124A1-20140102-C00005
  • For example, in WO/2003/051797N,N′-Di-tBoc-N-methyl-1H-pyrazole-1-carboxamidine has been used to prepare an N-methyl guanidine in an unrelated chemical family.
  • Other compounds of the invention may be made in similar ways using related synthetic methods with, if appropriate, suitable protecting groups compatible with the synthetic methodology.
  • Compounds of formula (X) where R is —N═C(R8)—NR9R10 (amidines) where R8 is hydrogen, alkyl, substituted alkyl or aryl and R9 and R10 can be alkyl, substituted alkyl or aryl or R9 and R10 can form a ring may be prepared by reaction of a compound of formula (VIII) with a compound of formula (IX) to afford compounds of formula (X).
  • R11 is preferably lower alkyl and typical examples of compound (VIII) are Dimethylformamide dimethylacetal (DMF.DMA) and Dimethylacetamide dimethylacetal (DMA.DMA).
  • Figure US20140005124A1-20140102-C00006
  • Below are specific examples of the preparation of certain compounds of the invention by the above general procedures.
  • Guanidine and Amidine Analogues of 3-[(2-aminoethylthio]-cyclosporin A
    • Example A 3-[(2-Guanidyl)-ethylthio]-cyclosporin A (III)
  • Figure US20140005124A1-20140102-C00007
  • To a solution of 3-[(2-aminoethylthio]-cyclosporin A*-(I)) (200 mg, 0.16 mmol) in methanol (20 mL) was added di-tBoc-pyrazole carboxamidine (250 mg, 0.8 mmol), and the reagents were stirred together for 18 h. After this time, a further portion of the di-Tt-pyrazole carboxamidine (100 mg, 0.32 mmol) was added and the reaction was stirred for a further 3 h. The reaction was then reduced in vacuo, redissolved in dichloromethane, washed with 0.5M citric acid, and the organic layer was dried over MgSO4 and reduced in vacuo. The product was then purified by chromatography column on a 10 g SPE cartridge eluting with diethyl ether to isolate 90 mg (40%) of desired product (II).
  • As the first member of the Guanidine and Amidine examples synthesized and because of the difficulties anticipated in characterising the final product (III), it was decided to fully and extensively characterize the di-tBoc protected guanidine (II) at this stage and to then take this material onto the free guanidine (III) by acid hydrolysis. Subsequent analogues in this Guanidine and Amidine subclass made from 3-[(2-aminoethylthio]-cyclosporin A were then characterised principally by MS
  • Compound (II) was analysed by 1H, 13C, DEPT NMR and subsequently by a series of 2-D NMR experiments, HMQC, HMBC and DEPT-HMQC.
  • Presence of the 3-[(2-Guanidyl)-ethylthio]side chain was confirmed by 1D & 2D NMR.
  • Analysis was performed in CDCl3 solution at 300K on a Bruker DRX500 spectrometer.
  • Figure US20140005124A1-20140102-C00008
  • 1H NMR Key Resonances:
  • δ=1.50, 1.51 ppm (2 singlets, 2×Boc, 18H, 6×CH3)
    δ=5.89 ppm, (singlet, sarcosine, 1H)
    • 2D Spectra
  • Using 1H detected Hetronuclear Multiple Quantum Coherence (HMQC), Hetronuclear Multiple Bond Correlation (HMBC) and edited Hetronuclear Single Quantum Coherence (DEPT-HSQC) experiments, connectivity and assignment may be made confirming the presence of the 3-[(2-Guanidyl)-ethylthio]side chain.
  • H (3) to 2′ (multiplet, 1H 2.84 ppm, 2H).
    2′ to 3′ (multiplet, 1H 3.67 ppm, 2H).
    3′ to NH 4′ (triplet JHH 5.8 Hz, 1H 8.67 ppm, 1H).
  • To a solution of the di-tBoc protected 3-[(2-Guanidyl)-ethylthio]-cyclosporin A (II) (21 mg, 0.0138 mmol) in dichloromethane (0.3 mL) was added trifluoroacetic acid (0.3 mL) and the solution was stirred at room temperature for 1 hour. The solution was concentrated to give the product (III) as a white solid (20 mg; 100%)
  • Analysis by MS (E+) showed a mass of 1320.2 (M+H) consistent with the proposed structure
    • Example B 3-[(2-N,N-dimethylformamidinyl)-1-thioethyl]-cyclosporin A (III)
  • Figure US20140005124A1-20140102-C00009
  • A mixed solution of 3-(1-thioethylamine)cyclosporine A (0.64 g, 0.5 mmol) and N,N-dimethylformamide dimethyl acetal in 20 mL of THF was refluxed for two hours. After removal of solvent under vacuum, the residue was subject to silica gel column using methylene/methanol (10:1) as eluents, 300 mg of pure product was obtained (yield: 45.0%)
  • MS (E+) showed a mass of 1332.82 (M+H+) consistent with the proposed structure.
  • Other methods will be apparent to a chemist skilled in the art as will methods for preparing starting materials and intermediates etc
  • In accordance with the present invention, the cyclosporin A derivatives may be applied, e.g. to an affected eye, in any efficacious concentration. When said cyclosporin A derivatives are applied to the eye as a topical ophthalmic composition the composition may comprise, 0.01 to saturation (e.g. greater than 20 weight percent) of said cyclosporin A derivative in a pharmaceutically acceptable excipient. From 0.01 to 50 weight percent, preferably from 0.1 to 20 weight percent, of cyclosporin A derivatives in a pharmaceutically acceptable excipient may be used. Such pharmaceutically acceptable excipients are, for example, animal oil, vegetable oil, an appropriate organic or aqueous solvent, an artificial tear solution, a natural or synthetic polymer, or an appropriate membrane to encapsulate the cyclosporin A derivative.
  • Specific examples of these pharmaceutically acceptable excipients are olive oil, arachis oil, castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, chremophor, Miglyol 182 (commercially available from Dynamit Nobel Kay-Fries Chemical Company, Mont Vale, N.J.), an alcohol (e.g. ethanol, n-propyl alcohol, or iso-propyl alcohol), liposomes or liposome-like products or a silicone fluid. Preferred excipients are dimethyl sulphoxide and olive oil. Mixtures of at least two of any suitable excipients may be used.
  • Examples of artificial tear excipients which can be advantageously used in the practice of this invention are isotonic sodium chloride, cellulose ethers such as hydroxypropylmethylcellulose and hydroxyethylcellulose, polyvinyl alcohol and available artificial tea solutions.
  • An example of a useful polymeric excipient is a polyoxyethylated castor oil.
  • Examples of pharmaceutically acceptable membranes which can be advantageously used in the practice of this invention are microdone, an artificial lipid membrane, polyvinyl alcohol, or methylcellulose.
  • The cyclosporin A derivatives are advantageously administered topically as an ophthalmic drop (solution or suspension) or ophthalmic ointment containing an effective amount of the derivative. Concentrations of 0.01 to 50 weight percent, preferably 0.1 to 20 weight percent, of the cyclosporin A derivatives are used in the practice of the present invention.
  • In accordance with a method of the present invention, at least one of the cyclosporin A derivatives is administered topically in any quantity required to provide the degree of treatment needed. For example, 5 microliters to 1 milliliter of a solution, suspension, or ointment containing an effective amount of the cyclosporin A derivative, such as 0.01 to 50 weight percent, preferably 0.1 to 20 weight percent, of the cyclosporin A derivative is advantageously used.
  • Numerous advantages accrue with the practice of the present invention. The method of the present invention is useful in that it can locally prevent activation of a presystemic response.
  • Topical administration of the cyclosporin A derivatives to a patient's tear deficient eye increases tear production in the eye. Thus, such treatment further serves to correct corneal and conjunctival disorders exacerbated by tear deficiency and KCS, such as corneal scarring, corneal ulceration, inflammation of the cornea or conjunctiva, filamentary keratisis, mucopurulent discharge and vascularization of the cornea. Furthermore, the cyclosporin A derivatives directly decrease the immune response and granulation and neovascularization.
    • Example 1
  • This example compares the relative potency of the cyclosporine analogues utilized in the method of the present invention with cyclosporine A in modulating Jurkat T cell functions.
    • A. Inhibition of T Cell Proliferation.
  • In this experiment the % Viable cells @ 10 uM for 48 hours is determined by WST Assay (Water Soluble Tetrazolium).
  • Compound % Viable cells
    Cyclosporin A 57
    CsA-A1 45
    CsA-A2 62
    CsA-A3 72
    CsA-A4 65
    CsA-A5 78
    CsA-A6 94
  • The results of this experiment shows that the cyclosporine analogues utilized in the method of the present invention are as good or better than cyclosporine A.
  • B. Induction of T cell apoptosis
  • The percentage (%) of apoptic T cells is determined @ 10 uM compound concentration for 24 hours of incubation period.
  •
    Cyclosporin A 51
    CsA-A1 62
    CsA-A2 31
    CsA-A3 18
    CsA-A4 34
    CsA-A5 25
    CsA-A6 14
  • Again, the compound CsA-A1 shows surprisingly greater effect than cyclosporine A.
    • C. Suppression of IL-2 Production by T Cells
  • The percentage (%) inhibition in IL-2 production is determined 10 uM compound concentration for 24 hours of incubation period.
  •
    Cyclosporin A 100
    CsA-A 1 100
    CsA-A2 82
    CsA-A3 28
    CsA-A4 19
    CsA-A5 36
    CsA-A6 4
  • The compound CsA-A1, surprisingly, shows equivalent effectiveness as compared to cyclosporine A in this experiment.
  • As a result of the experiments described in Example 1, CsA-A1 was selected for further work.
    • Example 2
  • This example compares the relative potency of CsA-A1, the most preferred cyclosporine A derivative utilized in the method of the present invention with cyclosporine A in an in-vivo modal of ocular inflammation.
  • A. Rat EIU Model: Acute Intraocular Inflammation
  • Rats were injected in the foot pad LPS (100 ug/rat.) 5 rats were treated in each of the following groups. The topical vehicle was the Restasis vehicle.
  • The systemic vehicle was:
  •
    Ethanol (200 Proof) 15%
    Cremaphor EL 15%
    Polysorbate 80  2%
    Water 68%
  • Topically (t.i.d.) Systemically (i.p., b.i.d)
    Vehicle 25 mg/kg Cyclosporin A (ethanol)
    0.05% Cyclosporin 25/mg/kg CsA-A1(ethanol)
    0.05% CsA-A1
  • Samples of the blood and aqueous humor were collected and analyzed 24 hours post LPS injection. The histology of the cells was also recorded The results are shown in FIG. 1.A. As can be observed in FIGS. 1 A through E CsA-A1 showed a similar potency to cyclosporine A in inhibiting acute intraocular inflammation when applied topically and/or systemically in this experiment.
  • This example compares the relative potency of CsA-A1, the most preferred cyclosporine A derivative utilized in the method of the present invention with cyclosporine A in an in-vivo modal of ocular inflammation.
  • B. Rat EAU Model: Chronic Intraocular Inflammation Rats were immunized with R16 (RIBP immunogenic peptide, 100 ug/rat. The rats were then fitted with Alzet Pump to deliver 5 mg/kg/day of the test sample, below, or injected intraperitoneal with 10 mg/kg, q.d. of the test sample. 5 rats were treated in each of the following groups. The vehicle was
  •
    Ethanol (200 Proof) 15%
    Cremaphor EL 15%
    Polysorbate 80  2%
    Water 68%
  • In vivo fluorophotometry was performed on days 9, 12 and 14 post immunization. Aqueous samples and globes were collected and analyzed on day 14.
  • The results are shown in FIG. 2. s can be observed in FIGS. 2 A through 2K E CsA-A1 showed a similar potency to cyclosporine A in inhibiting acute intraocular inflammation when applied by intraperitoneal injection in this experiment. However, as a result of its lower solubility in the vehicle, it appeared to be less effective when applied by the Alzet Pump.
  • The Rat EAU model is indicative of autoimmune-mediated inflammatory conditions. Indeed, uveitis may precede, accompany or develop following the onset of many systemic autoimmune diseases including juvenile rheumatoid arthritis (RA), psoriatic arthritis, multiple sclerosis (MS), inflammatory bowel disease and systemic lupus erythematosus. The etiology of these chronic inflammatory conditions is not well understood; however, evidence suggests that autoreactive T cells and antibodies recognizing self-antigens localized within affected tissues drives the chronic inflammatory response, e.g. uveal and/or retinal antigens, myelin proteins within central nervous system or components of cartilage in patients with uveitis, MS and RA respectively. In any case, environmental factors (e.g. viral or bacterial infection) in the context of a genetic predisposition (e.g. mutations in genes encoding HLA) are thought to break self-tolerance and trigger the onset of disease. This concept is exemplified in EAU and other models of autoimmune-mediated disease. Lewis rats immunized with uveal or retinal antigens, including S-antigen or interphotoreceptor retinoid binding protein (IRBP), exhibit similar clinical and histological disease profiles compared to patients with posterior uveitis. Genetically susceptible strains of mice immunized with type II collagen show histopathological and clinical similarities to patients with rheumatoid arthritis. Likewise, immunization with myelin peptides mimics the immunpathogenesis of MS, including myelin loss within white matter tracts of the CNS and paralysis, and these mice may also develop uveitis.
  • Further objects of this invention, together with additional features contributing thereto and advantages accruing therefrom will be apparent from the following examples of the invention.
  • The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention was to be governed only by the lawful construction of the appended claims. In particular, although the method of the present invention has been described with the use of the specific cyclosporine A derivatives of the above formula, the novel cyclosporine derivatives that may be used in the method of the present invention further include 3-substituted iminoalkylthio cyclosporin A derivatives, preferably 3-substituted diaminoiminoalkylthio cyclosporin A derivatives, e.g. ((R)-(diamino)iminoalkyllthio-Sar)3-(4′-hydroxy-MeLeu)4 cyclosporin A, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar)3-(4′-hydroxy-MeLeu)4-cyclosporin A, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar)3-cyclosporin A derivatives and ((R)-(diamino)iminoalkylthio-Sar)3-cyclosporin A derivatives.
  • The invention may be summarized as follows.
  • 1. A method for the treatment of an inflammatory disease, disorder or condition of a mammal, comprising the step of administering to a patient in need thereof, a therapeutically effective amount of a cyclosporin A derivative selected from the group consisting of compounds represented by the formula:
  • Figure US20140005124A1-20140102-C00010
  • wherein R1 is S-Alk-R wherein Alk is an alkylene linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
  • 2. The method of 1 wherein Alk is a methylene or a C3 to C6 alkenylenyl linkage.
  • 3. The method of 1 wherein R1 is a methylene or a C2 to C6 polymethylene linkage.
  • 4. The method of 1 wherein R1 is a C3 to C6 alkenylenyl linkage.
  • 5. The method of 1 wherein R is —N═C(NR3R4)(NR5R6) or —NR7C(NR3)(C═NR5), wherein R3-R7 is H, Alk, Ar or (CH2)nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R3 and R4 or R4 and R5 or R5 and R7 or R3 and R7, together may be —CH2—CH2— or —CH2—CH2—CH2—.
  • 6. The method of 1 wherein said cyclosporine A derivative is a 3-substituted diaminoiminoalkylthio cyclosporine A derivative.
  • 7. The method of 1 wherein said cyclosporine A derivative is selected from the group consisting of ((R)-(diamino)iminoalkyllthio-Sar)3-(4′-hydroxy-MeLeu)4 cyclosporin A derivatives, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar)3-(4′-hydroxy-MeLeu)4-cyclosporin A, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar)3-cyclosporin A derivatives and ((R)-(diamino)iminoalkylthio-Sar)3-cyclosporin A derivatives.
  • 8. The method of 1 wherein said cyclosporine A derivative is selected from the group of compounds according to 1 wherein R1 is —S(CH2)2N═C(NH2)2 and R2 is —CH2CH(CH3)2, —CH2C(OH)(CH3)2, —CH(CH3)2 or —CH(CH3)CH2CH3.
  • 9. The method of 1 wherein the compound is administered in a composition comprising 0.1 to 20 wt % of the compound together with a pharmaceutically acceptable excipient.
  • 10. The method of 9 wherein the pharmaceutically acceptable excipient is selected from the group consisting of animal oil and vegetable oil.
  • 11. The method of 9 wherein the pharmaceutically acceptable excipient is selected from the group consisting of olive oil, arachis oil, castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, silicone fluid and mixtures thereof.
  • 12. The method of 1 wherein R1 is a hydrogen atom or a radical of formula (Ia):

  • —S-Alk-R1  (Ia)
  • in which
  • Alk-R11 represents a methyl radical, or alternatively
  • Alk represents a C2-C6 straight chain or branched alkylene radical or a C3-C6 cycloalkylene radical, and
  • R11. represents
  • a hydrogen atom or a hydroxyl, carboxyl or alkyloxycarbonyl radical, or
  • an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or a phenyl, alkyl, C2-C4 alkenyl or C3-C6 cycloalkyl radical, said radical optionally substituted with selected from a halogen atom, an alkyloxy, alkyloxycarbonyl, amino, alkylamino and dialkylamino radical; or
  • R12 and R13 represent a benzyl or saturated or unsaturated heterocycylic radical, said heterocycylic radical containing from 5 to 6 ring members and from 1 to 3 heteroatoms;
  • or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 6-membered heterocycle, which heterocycle having an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or R1 is a radical of the formula (Ib): —N(R14)—(CH2)n—NR12R13 in which R12 and R13 are as defined above, R14 represents a hydrogen atom or an alkyl radical and n is an integer ranging from 2 to 4,
  • and R2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl,
  • with the proviso that, when R1 is a hydrogen atom, then R2 is not an alkyl butyl? radical, and wherein the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof.
  • 13. The method of 12 wherein in the cyclosporine A derivatives of the formula, the trans butene moiety, which is normally present in the 1-position of cyclosporine A, is replaced with R15 wherein R15 represents a radical of formula
  • —CH2CHCHCH2—R16 (Ic) or —CH2SR17 (Id), wherein R16 represents an alkylthio, aminoalkylthio, alkylaminoalkylthio, dialkylaminoalkylthio, pyrimidinylthio, thiazolylthio, N-alkylimidazolylthio, hydroxyalkylphenylthio, hydroxyalkylphenyloxy, nitrophenylamino or 2-oxopyrimidin-1-yl radical and R17 represents an alkyl radical.
  • 14. The method of 12 wherein R represents
  • a hydroxyl radical,
  • a carboxyl radical,
  • an alkyloxycarbonyl radical,
  • an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom, or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represent a benzyl or heterocyclyl radical, wherein said heterocyclyl radical may be saturated or unsaturated and contains 5 or 6 ring members and from 1 to 3 heteroatoms; or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or
  • a radical of the formula —N(R14)—(CH2)n—NR12R13 in which R12 and R13 are as defined above R.14 represents a hydrogen atom or an alkyl radical, and n is an integer from 2 to 4;
  • wherein the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms;
  • or a pharmaceutically acceptable salt thereof.
  • 15. The method of 14, wherein:
  • Alk represents a C3-C6 straight chain or branched alkylene radical, and
  • R represents
  • a hydroxyl radical, or
  • an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl, C3-4 alkenyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represents a benzyl radical; or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl radical;
  • or a pharmaceutically acceptable salt thereof.
  • 16. The method of 14, wherein:
  • Alk represents a C2-6 straight chain or branched alkylene radical, and
  • R represents a hydroxyl radical, or an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl, allyl, phenyl or benzyl radical; or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a heterocycle selected from azetidinyl, piperidyl, piperazinyl, N-methylpiperazinyl, N-phenylpiperazinyl, N-benzylpiperazinyl, morpholino, tetrahydropyridyl, methyltetrahydropyridyl and phenyltetrahydropyridyl;
  • or a pharmaceutically acceptable salt thereof.
  • 17. The method of 16, wherein the cyclosporine A derivative is selected from the group consisting of [(R)-2-(N,N-dimethyl-amino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(1-piperidyl)-ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(N-methyl-N-t-butylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(hydroxy)-ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(N,N-diethyl-amino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(N,N-dimethylamino)ethylthio-Sar]3-cyclosporin A,
    • [(R)-2-(1-piperidyl)ethylthio-Sar]3-cyclosporin A,
    • [(R)-2-(N-methyl-N-1-propylamino)ethylthio-Sar]3-cyclosporin A and
    • [(R)-2-(N-methyl-N-t-butylamino)ethylthio-Sar]3-cyclosporin A, and pharmaceutically acceptable salts thereof.
  • 18. The method of 16, wherein the cyclosporine A derivative is (R)-(diethylaminoethylthio-Sar)3 cyclosporin A,
  • 19. A method of treating inflammatory diseases selected from the group consisting of ocular inflammatory diseases, dermal inflammatory diseases, inflammatory rheumatic diseases, inflammatory bowel disease, neuroinflammatory diseases and autoimmune hematological diseases and disorders wherein said cyclosporine A derivative is selected from the group consisting of compounds represented by the formula:
  • Figure US20140005124A1-20140102-C00011
  • wherein R1 is S-Alk-R wherein Alk is an alkylene or alkylenyl linkage, R is
  • —N═C(NR3R4)(NR5R6) or —NR7[(NR3R4)C═NR5], or —N═C(R8)(NR9R10), wherein R3-R7 10 is H, Alk, Ar or (CH2)nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R3 and R4, or R4 and R5, or R5 and R7, or R3 and R7, or R9 and R10, or R8 and R9, together, may be —(CH2)x—, wherein x is an integer of from 2 to 5 and R2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl-substituted lower alkyl.
  • 20. The method of 19 wherein R1 is a methylene or a C2 to C6 polymethylene linkage.
  • 21. The method of 19 wherein R1 is a C3 to C6 alkenylenyl linkage.
  • 22. The method of 19 wherein R is —N═C(NR3R4)(NR5R6) or —NR7C(NR3)(C═NR5), wherein R3-R7 is H, Alk, Ar or (CH2)nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R3 and R4 or R4 and R5 or R5 and R7 or R3 and R7, together may be —CH2—CH2— or —CH2—CH2—CH2—.
  • 23. The method of 19 wherein said cyclosporine A derivative is a 3-substituted diaminoiminoalkylthio cyclosporine A derivative.
  • 24. The method of 19 wherein said cyclosporine A derivative is selected from the group consisting of ((R)-(diamino)iminoalkyllthio-Sar)3-(4′-hydroxy-MeLeu)4 cyclosporin A derivatives, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar)3-(4′-hydroxy-MeLeu)4-cyclosporin A, ((R)-(alkyl)(dialkylamino)iminoalkylthio-Sar)3-cyclosporin A derivatives and ((R)-(diamino)iminoalkylthio-Sar)3-cyclosporin A derivatives
  • 25. The method of 19 wherein R1 is a hydrogen atom or a radical of formula (Ia):

  • —S-Alk-R1  (Ia)
  • in which
  • Alk-R11 represents a methyl radical, or alternatively
  • Alk represents a C2-C6 straight chain or branched alkylene radical or a C3-C6 cycloalkylene radical, and
  • R11. represents
  • a hydrogen atom or a hydroxyl, carboxyl or alkyloxycarbonyl radical, or
  • an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or a phenyl, alkyl, C2-C4 alkenyl or C3-C6 cycloalkyl radical, said radical optionally substituted with selected from a halogen atom, an alkyloxy, alkyloxycarbonyl, amino, alkylamino and dialkylamino radical; or
  • R12 and R13 represent a benzyl or saturated or unsaturated heterocycylic radical, said heterocycylic radical containing from 5 to 6 ring members and from 1 to 3 heteroatoms;
  • or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated 4- to 6-membered heterocycle, which heterocycle having an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or R1 is a radical of the formula (Ib): —N(R14)—(CH2)n—NR12R13 in which R12 and R13 are as defined above, R14 represents a hydrogen atom or an alkyl radical and n is an integer ranging from 2 to 4,
  • and R2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl substituted lower alkyl,
  • with the proviso that, when R1 is a hydrogen atom, then R2 is not an alkyl butyl? radical, and wherein the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof.
  • 26. The method of 25 wherein in the cyclosporine A derivatives of the formula, the trans butene moiety, which is normally present in the 1-position of cyclosporine A, is replaced with R15 wherein R15 represents a radical of formula
  • —CH2CHCHCH2—R16 (Ic) or —CH2SR17 (Id), wherein R16 represents an alkylthio, aminoalkylthio, alkylaminoalkylthio, dialkylaminoalkylthio, pyrimidinylthio, thiazolylthio, N-alkylimidazolylthio, hydroxyalkylphenylthio, hydroxyalkylphenyloxy, nitrophenylamino or 2-oxopyrimidin-1-yl radical and R17 represents an alkyl radical.
  • 27. The method of 25 wherein R represents
  • a hydroxyl radical,
  • a carboxyl radical,
  • an alkyloxycarbonyl radical,
  • an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom, or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represent a benzyl or heterocyclyl radical, wherein said heterocyclyl radical may be saturated or unsaturated and contains 5 or 6 ring members and from 1 to 3 heteroatoms; or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl, phenyl or benzyl radical, or
  • a radical of the formula —N(R14)—(CH2)n—NR12R13 in which R12 and R13 are as defined above R.14 represents a hydrogen atom or an alkyl radical, and n is an integer from 2 to 4;
  • wherein the alkyl portions or radicals defined above are straight chain or branched and contain from 1 to 4 carbon atoms;
  • or a pharmaceutically acceptable salt thereof.
  • 28. The method of 27, wherein:
  • Alk represents a C3-C6 straight chain or branched alkylene radical, and
  • R represents a hydroxyl radical, or an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl, C3-4 alkenyl or optionally substituted phenyl radical, wherein said phenyl radical may be substituted by a halogen atom or an alkyloxy, alkyloxycarbonyl, amino, alkylamino or dialkylamino radical, or represents a benzyl radical; or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4 to 6 ring members, which heterocycle may optionally contain an additional heteroatom selected from nitrogen, oxygen and sulphur, and wherein said saturated or unsaturated heterocycle is optionally substituted by an alkyl radical;
  • or a pharmaceutically acceptable salt thereof.
  • 29. The method of 27, wherein:
  • Alk represents a C2-6 straight chain or branched alkylene radical, and
  • R represents a hydroxyl radical, or an —NR12R13 radical in which R12 and R13, which are identical or different, represent a hydrogen atom or an alkyl, allyl, phenyl or benzyl radical; or in which R12 and R13 form, together with the nitrogen atom to which they are attached, a heterocycle selected from azetidinyl, piperidyl, piperazinyl, N-methylpiperazinyl, N-phenylpiperazinyl, N-benzylpiperazinyl, morpholino, tetrahydropyridyl, methyltetrahydropyridyl and phenyltetrahydropyridyl;
  • or a pharmaceutically acceptable salt thereof.
  • 30. The method of 29, wherein the cyclosporine A derivative is selected from the group consisting of
    • [(R)-2-(N,N-dimethyl-amino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(1-piperidyl)-ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(N-methyl-N-t-butylamino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(hydroxy)-ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(N,N-diethyl-amino)ethylthio-Sar]3-[4′-hydroxy-MeLeu]4-cyclosporin A,
    • [(R)-2-(N,N-dimethylamino)ethylthio-Sar]3-cyclosporin A,
    • [(R)-2-(1-piperidyl)ethylthio-Sar]3-cyclosporin A,
    • [(R)-2-(N-methyl-N-1-propylamino)ethylthio-Sar]3-cyclosporin A and
    • [(R)-2-(N-methyl-N-t-butylamino)ethylthio-Sar]3-cyclosporin A, and pharmaceutically acceptable salts thereof.
  • 31. The method of 30, wherein the cyclosporine A derivative is (R)-(diethylaminoethylthio-Sar)3 cyclosporin A,
  • 32. The method of 19 wherein said ocular inflammatory disease is keratoconjunctivitis sicca, vernal keratoconjunctivitis, allergic conjunctivitis, or uveitis
  • 33. The method of 19 wherein said dermal inflammatory disease is psoriasis or atopic dermatitis),
  • 34. The method of 19 wherein said inflammatory rheumatic disease is rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Wegener granulamatosis, polymyositis, dermatomyositis, psoriatic arthritis, ankylosing spondylitis, Reiter's syndrome or juvenile rheumatoid arthritis),
  • 35. The method of 19 wherein said ocular inflammatory bowel disease is ulcerative colitis or Crohn's disease.
  • 36. The method of 19 wherein said neuroinflammatory disease is multiple sclerosis.
  • 37. The method of 19 wherein said ocular autoimmune hematological disorder is hemolytic anaemia, aplastic anaemia, pure red cell anaemia, or idiopathic thrombocytopaenia.

Claims (1)

What is claimed is:
1. A method for the treatment of an inflammatory condition of a mammal, comprising the step of administering to a patient in need thereof, a therapeutically effective amount of a cyclosporin A derivative represented by the following formula:
Figure US20140005124A1-20140102-C00012
wherein R1 is S-Alk-R wherein Alk is an alkylene linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
US14/014,728 2009-05-27 2013-08-30 Cyclosporin derivatives for treating inflammatory diseases and conditions Abandoned US20140005124A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/014,728 US20140005124A1 (en) 2009-05-27 2013-08-30 Cyclosporin derivatives for treating inflammatory diseases and conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18138209P 2009-05-27 2009-05-27
US12/785,133 US8524671B2 (en) 2009-05-27 2010-05-21 Cyclosporin derivatives for treating inflammatory diseases and conditions
US14/014,728 US20140005124A1 (en) 2009-05-27 2013-08-30 Cyclosporin derivatives for treating inflammatory diseases and conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/785,133 Continuation US8524671B2 (en) 2009-05-27 2010-05-21 Cyclosporin derivatives for treating inflammatory diseases and conditions

Publications (1)

Publication Number Publication Date
US20140005124A1 true US20140005124A1 (en) 2014-01-02

Family

ID=42797341

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/785,133 Active 2031-06-06 US8524671B2 (en) 2009-05-27 2010-05-21 Cyclosporin derivatives for treating inflammatory diseases and conditions
US14/014,728 Abandoned US20140005124A1 (en) 2009-05-27 2013-08-30 Cyclosporin derivatives for treating inflammatory diseases and conditions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/785,133 Active 2031-06-06 US8524671B2 (en) 2009-05-27 2010-05-21 Cyclosporin derivatives for treating inflammatory diseases and conditions

Country Status (6)

Country Link
US (2) US8524671B2 (en)
EP (1) EP2435065A1 (en)
JP (1) JP2012528163A (en)
AU (1) AU2010254316A1 (en)
CA (1) CA2763207A1 (en)
WO (1) WO2010138423A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US10544335B2 (en) 2014-10-31 2020-01-28 Dow Global Technologies Llc Tackifier and a continuous process for producing the tackifier

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
EP2964269A1 (en) 2013-03-08 2016-01-13 Allergan, Inc. Cyclosporine a-steroid conjugates
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350442B2 (en) * 1999-04-13 2002-02-26 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6583265B1 (en) * 1998-06-12 2003-06-24 C-Chem Ag Cyclosporins
US20100009953A1 (en) * 2008-07-10 2010-01-14 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
JP3034806B2 (en) * 1996-08-28 2000-04-17 富士インジェクタ株式会社 Rotary switching mechanism in rotary switching valve
FR2757520B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2757522B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2757521B1 (en) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2762843B1 (en) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6346511B1 (en) * 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
FR2772768B1 (en) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES
FR2780061B1 (en) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583265B1 (en) * 1998-06-12 2003-06-24 C-Chem Ag Cyclosporins
US6350442B2 (en) * 1999-04-13 2002-02-26 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US20100009953A1 (en) * 2008-07-10 2010-01-14 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions
US8716238B2 (en) * 2008-07-10 2014-05-06 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions
US20140200185A1 (en) * 2008-07-10 2014-07-17 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10544335B2 (en) 2014-10-31 2020-01-28 Dow Global Technologies Llc Tackifier and a continuous process for producing the tackifier
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized

Also Published As

Publication number Publication date
US20100305037A1 (en) 2010-12-02
WO2010138423A1 (en) 2010-12-02
CA2763207A1 (en) 2010-12-02
AU2010254316A1 (en) 2011-12-22
EP2435065A1 (en) 2012-04-04
US8524671B2 (en) 2013-09-03
JP2012528163A (en) 2012-11-12

Similar Documents

Publication Publication Date Title
AU2009268549B2 (en) Cyclosporin derivatives for treating ocular and dermal diseases and conditions
EP1802650B1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
US7718767B2 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US20140005124A1 (en) Cyclosporin derivatives for treating inflammatory diseases and conditions
US7632807B2 (en) Cyclosporin alkynes and their utility as pharmaceutical agents
US9266927B2 (en) Cyclosporin A analogs

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION